Manufacturing Chemist has flagged technology transfer as "the hidden bottleneck in pharmaceutical value realisation" — a framing that should prompt R&D managers to re-examine how their organisations move processes between sites, scales and partners.

The trade publication's argument lands at a moment when transfer activity is rising across the sector. Sponsors increasingly split development and manufacturing geographically, contract development and manufacturing organisations (CDMOs) take on later-stage work, and platform technologies such as biologics and advanced therapy medicinal products multiply the number of handoffs a single product must survive before it reaches commercial supply. Each handoff is a point where value can leak.

The core of the problem is familiar to anyone who has run a transfer: a process that performs predictably in one facility does not automatically reproduce that performance in another. Equipment differences, operator practice, analytical method variability and documentation gaps all conspire against seamless replication. The result is rework, delayed regulatory filings, extended tech-transfer timelines and, in the worst cases, batches that fail specifications at the receiving site after passing them at the sending one.

For portfolio managers, the financial stakes are considerable. Every month of transfer delay on a marketed product postpones revenue; on a pipeline asset, it pushes back the launch window in which exclusivity is monetised. Transfers are therefore not a technical afterthought but a direct driver of net present value. Treating them as such — with dedicated governance, realistic timelines and explicit budgets — is the practical implication of the bottleneck thesis.

The editorial also implies an organisational critique. Transfer failures rarely stem from a single catastrophic error. They accumulate from under-specified process knowledge, tacit know-how that never leaves the originator's laboratory, and receiving teams brought into the project too late to influence its design. R&D leaders who wait until Phase III to document critical process parameters typically pay for that delay twice: once in the transfer itself, and again when regulators ask for justification of the control strategy.

What does good practice look like? The trade literature converges on several principles. Start transfer planning at process characterisation, not at facility selection. Capture explicit and tacit knowledge in parallel — the documented recipe and the operating judgement behind it. Bring quality and regulatory functions into scoping early. Define success criteria numerically before the first engineering batch, so that both sender and receiver agree on what comparable performance means. And build in a formal gap assessment when equipment trains differ, rather than assuming equivalence.

CDMO relationships deserve particular scrutiny under this lens. The sponsor retains accountability for the product even as operational control moves to the partner, and a poorly executed transfer can strand institutional knowledge on one side of the contract. Due diligence on a CDMO's transfer track record — not just its capacity and price — is a portfolio decision, not a procurement formality.

The Manufacturing Chemist piece ultimately positions technology transfer as a discipline in its own right, worthy of the same rigour applied to discovery and clinical development. That is a standard many organisations still fail to meet. For R&D and operations leaders, the actionable question is straightforward: can your organisation state, with evidence, how long its last three transfers took, what they cost, and where each one lost time? Where that data does not exist, the bottleneck is not hidden — it is simply unmeasured.